| Specificity |
The antibody is recommended as a detection antibody in a pharmacokinetic (PK) bridging assay with capture antibody GenScript, A01991-40, MonoRab™ Anti-Cetuximab Antibody (69H10), mAb, Rabbit. |
| Host Species |
Rabbit |
| Immunogen |
Cetuximab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.01-0.1 µg/ml |
| Competitive ELISA |
10-50 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
Lyophilized with PBS, pH 7.4, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Rabbit IgG |
| Clonality |
Monoclonal |
| Clone ID |
90G3 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
ELISA binding of MonoRabᵀᴹ Anti-Cetuximab Antibody (90G3), mAb, Rabbit (GenScript, A01992-40) with Cetuximab. While the antibody does not recognize the human IgG Fc fragment (data not shown).
Coating antigen: Cetuximab, 1 µg/ml.
MonoRabᵀᴹ Anti-Cetuximab Antibody (90G3), mAb, Rabbit (GenScript, A01992-40) dilutions start from 1000 ng/ml.
EC₅₀= 13.25 ng/ml.
Standard curve of Cetuximab Sandwich ELISA. The Cetuximab Sandwich ELISA assay is developed by using MonoRabᵀᴹ Anti-Cetuximab Antibody (69H10), mAb, Rabbit (GenScript, A01991-40) and MonoRabᵀᴹ Anti-Cetuximab Antibody (90G3), mAb, Rabbit (Genscript, A01992-40) as the capture and detection antibodies, respectively.
In this ELISA assay, MonoRabᵀᴹ Anti-Cetuximab Antibody (90G3), mAb, Rabbit (GenScript, A01992-40) was labeled with Biotin.
GenScript can provide customized conjugation services for this product per the customer's request.
The sensitivity of detecting Cetuximab is up to 40 pg/ml.
MonoRabᵀᴹ Anti-Cetuximab Antibody (90G3), mAb, Rabbit (GenScript, A01992-40) blocks Cetuximab binding with EGFR protein.
Coating antigen: EGFR, 0.5 μg/ml.
Cetuximab final concentration: 20 ng/ml.
MonoRabᵀᴹ Anti-Cetuximab Antibody (90G3), mAb, Rabbit (GenScript, A01992-40) dilutions start from 10 μg/ml.
IC₅₀= 15.32 ng/ml
ELISA binding of MonoRab™ Anti-Cetuximab Antibody (90G3), mAb, Rabbit (GenScript, A01992-40) with Cetuximab. While the antibody does not recognize the human IgG Fc fragment (data not shown).
Coating antigen: Cetuximab, 1 µg/ml.
MonoRab™ Anti-Cetuximab Antibody (90G3), mAb, Rabbit (GenScript, A01992-40) dilutions start from 1000 ng/ml.
EC50= 13.25 ng/ml.
| Target Background |
Cetuximab is a recombinant human/mouse chimeric monoclonal antibody against epidermal growth factor receptor (EGFR). It is composed of the antigen-binding regions of mouse anti EGFR monoclonal antibody specific for the N-terminal portion of human EGFR with human IgG1 heavy and kappa light chain constant regions. Cetuximab is marketed under the brand Erbitux by Eli Lilly Company. It was approved by the US Food and Drug Administration for the treatment of metastatic colorectal cancer and metastatic non-small cell lung cancer.GenScript MonoRab™ Anti-Cetuximab Antibody (90G3), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Cetuximab. |
| Synonyms |
Rabbit monoclonal to Erbitux |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
